Calidi Biotherapeutics, Inc. (CLDI) Stock Price & Analysis
Calidi Biotherapeutics, Inc. (CLDI) fell 4.76% to USD 0.1 as of July 25, 2026 at 18:21 UTC, according to Nexqual real-time market data.
CLDI last closed at USD 0.11; the session ranged USD 0.1–0.11 on volume of 39,581,308 shares. Market capitalization is $1.93M, with a 52-week range of USD 0.1–10.92 (ASE). Source: Nexqual, July 25, 2026 at 18:21 UTC.
Key Statistics (as of July 25, 2026 at 18:21 UTC)
| Price | USD 0.1 |
|---|---|
| Change | ▼ 4.76% (down) |
| Previous Close | USD 0.11 |
| Open | USD 0.11 |
| Day Range | USD 0.1 – 0.11 |
| 52-Week Range | USD 0.1 – 10.92 |
| Volume | 39,581,308 shares |
| Market Cap | $1.93M |
| Exchange | ASE |
Technical Analysis (CLDI)
Nexqual's technical model rates CLDI "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 18:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.76 (oversold) |
| vs SMA50 | Below (USD 0.16) |
| MACD | -0.02 (negative) |
Analyst Ratings (CLDI)
Wall Street analysts rate CLDI "None", per Nexqual as of July 25, 2026 at 18:21 UTC.
| Consensus Rating | None |
|---|
Earnings (CLDI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -2.21 vs est -1.68 ▼ miss |
| 2025-06-30 | USD -1.99 vs est -1.32 ▼ miss |
| 2025-03-31 | USD -2.25 vs est -1.8 ▼ miss |
| 2024-12-31 | USD -3.24 vs est -4.44 ▲ beat |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Financials & Fundamentals (CLDI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -312.39% |
| Debt / Equity | 45.74 |
| Current Ratio | 1.92 |
| Total Cash | $6.63M |
| Total Debt | $2.26M |
| Free Cash Flow | $-9.41M |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Financial Health Score (CLDI)
Nexqual rates Calidi Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 18:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $7M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Critical — ROE -312%, ROA -98.2% |
Ownership (CLDI)
| Insider Ownership | +1.87% |
|---|---|
| Institutional Ownership | +10.46% |
| Shares Outstanding | 19.31M |
| Float | 19.00M |
| Short % of Float | +18.02% |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
Leadership (CLDI)
Calidi Biotherapeutics, Inc. is led by Eric E. Poma (age 53), CEO & Director, per Nexqual as of July 25, 2026 at 18:21 UTC.
| CEO & Director | Eric E. Poma (age 53) |
|---|---|
| CFO & Corporate Secretary | Andrew C. Jackson (age 56) |
| Head of Technical Operations & Chief Scientific Officer | Antonio Fernandez Santidrian Ph.D., Pharm.D. (age 45) |
Major Backers & Investors (CLDI)
Notable institutional backers of Calidi Biotherapeutics, Inc. include Armistice Capital, LLC, Sabby Management, LLC, Warberg Asset Management LLC, according to Nexqual as of July 25, 2026 at 18:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 4.55% |
| Sabby Management, LLC | 2.25% |
| Warberg Asset Management LLC | 1.29% |
| HighTower Advisors, LLC | 0.43% |
| Virtu Financial LLC | 0.39% |
| Fidelity | 0.31% |
| Rs Crum Inc. | 0.21% |
| Arax Advisory Partners | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.33% |
| Vanguard Group | 0.26% |
Source: Nexqual, July 25, 2026 at 18:21 UTC.
From Calidi Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.   Prior to commencing an initial clinical trial in humans with a product candidate in the U.S., an IND must be submitted to the FDA and the FDA must allow the IND to proceed.
- Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites.
- We maintain agreements with our manufacturers that include confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates.
- We expect to continue to invest in building proprietary processes that will enable us to be at a competitive advantage when manufacturing product candidates for our clinical programs.
Partnerships
- We have the right to terminate the agreement for any reason upon written notice to university and the agreement will terminate at the end of the Calendar Quarter following the Calendar Quarter during which we provided our notice of termination.     Collaboration Agreement with Personalized Stem Cells, Inc.   On April 9, 2020, we entered into a collaboration and license agreement with Personalized Stem Cells, Inc. (the " PSC Agreement ").
- A critical component of our success in this area will be through our research collaboration with our subsidiary, StemVac.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZTR | Azitra Inc | USD 0.13 | ▼ 3.08% |
| VTAK | Catheter Precision, Inc. | USD 0.26 | ▼ 32.64% |
| LRHC | La Rosa Holdings Corp. | USD 0.97 | ▲ 5.87% |
| BIVI | BioVie Inc. | USD 1.37 | ▲ 2.24% |
| BDRX | Biodexa Pharmaceuticals plc | USD 1.65 | ▼ 3.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 18:21 UTC. This page is informational and not investment advice.